{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:01:31Z","timestamp":1781114491531,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003508","name":"Universitat de Val\u00e8ncia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.trsl.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T19:35:38Z","timestamp":1598124938000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies"],"prefix":"10.1016","volume":"229","author":[{"given":"Federico V.","family":"Pallard\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Gonzalez-Cabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Lyakhovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Trifuoggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2020.08.009_bib0001","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"Campuzano","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2020.08.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2019.103419","article-title":"Mitochondrial dysfunction in neurons in Friedreich's ataxia","volume":"102","author":"Stepanova","year":"2020","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.trsl.2020.08.009_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox9080664","article-title":"Antioxidant therapies and oxidative stress in Friedreich's ataxia: the right path or just a diversion?","volume":"9","author":"Rodr\u00edguez","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.trsl.2020.08.009_bib0004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bmb\/ldx034","article-title":"Friedreich's ataxia: clinical features, pathogenesis and management","volume":"124","author":"Cook","year":"2017","journal-title":"Br Med Bull"},{"key":"10.1016\/j.trsl.2020.08.009_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jnc.12317","article-title":"Clinical features of Friedreich's ataxia: classical and atypical phenotypes","volume":"126 Suppl","author":"Parkinson","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.trsl.2020.08.009_bib0006","doi-asserted-by":"crossref","first-page":"12239","DOI":"10.1073\/pnas.220403797","article-title":"Frataxin activates mitochondrial energy conversion and oxidative phosphorylation","volume":"97","author":"Ristow","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.trsl.2020.08.009_bib0007","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/hmg\/ddi214","article-title":"Frataxin interacts functionally with mitochondrial electron transport chain proteins","volume":"14","author":"Gonz\u00e1lez-Cabo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2020.08.009_bib0008","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.276.5319.1709","article-title":"Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin","volume":"276","author":"Babcock","year":"1997","journal-title":"Science (80-)"},{"key":"10.1016\/j.trsl.2020.08.009_bib0009","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0897-345","article-title":"Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin","volume":"16","author":"Koutnikova","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2020.08.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104606","article-title":"Friedreich ataxia- pathogenesis and implications for therapies","volume":"132","author":"Delatycki","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.trsl.2020.08.009_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-981-13-9589-5_7","article-title":"Iron pathophysiology in Friedreich's ataxia","volume":"1173","author":"Li","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00264","article-title":"Reversible axonal dystrophy by calcium modulation in frataxin-deficient sensory neurons of YG8R mice","volume":"10","author":"Moll\u00e1","year":"2017","journal-title":"Front Mol Neurosci"},{"issue":"Suppl 1","key":"10.1016\/j.trsl.2020.08.009_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jnc.12303","article-title":"Mitochondrial pathophysiology in Friedreich's ataxia","volume":"126","author":"Gonz\u00e1lez-Cabo","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.trsl.2020.08.009_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/hmg\/9.2.275","article-title":"Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia","volume":"9","author":"Bradley","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2020.08.009_bib0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.1001","article-title":"Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia","volume":"49","author":"Lodi","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0016","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/hmg\/ddp592","article-title":"Molecular control of the cytosolic aconitase\/IRP1 switch by extramitochondrial frataxin","volume":"19","author":"Cond\u00f2","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2020.08.009_bib0017","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.55.11.1752","article-title":"Increased levels of plasma malondialdehyde in Friedreich ataxia","volume":"55","author":"Emond","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.trsl.2020.08.009_bib0018","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1046\/j.1365-2362.2001.00922.x","article-title":"Glutathione in blood of patients with Friedreich's ataxia","volume":"31","author":"Piemonte","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.trsl.2020.08.009_bib0019","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1017\/S0317167100022964","article-title":"Friedreich's ataxia in northern Italy. II. Biochemical studies in cultured cells","volume":"7","author":"Bertagnolio","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.trsl.2020.08.009_bib0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3389\/fnins.2019.01054","article-title":"Quantitative proteomic and network analysis of differentially expressed proteins in PBMC of Friedreich's Ataxia (FRDA) patients","volume":"13","author":"Pathak","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.trsl.2020.08.009_bib0021","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14737175.2017.1356721","article-title":"Pharmacological therapeutics in Friedreich ataxia: the present state","volume":"17","author":"Strawser","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.trsl.2020.08.009_bib0022","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archneur.62.4.621","article-title":"Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up","volume":"62","author":"Hart","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0023","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","article-title":"Coenzyme Q10 and vitamin e deficiency in Friedreich's ataxia: predictor of efficacy of vitamin e and coenzyme Q10 therapy","volume":"15","author":"Cooper","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0024","first-page":"1004","article-title":"Cerebellar ataxia and CoQ10 deficiency","volume":"1","author":"Quinzii","year":"2013","journal-title":"J Neurol Disord Stroke"},{"key":"10.1016\/j.trsl.2020.08.009_bib0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1212\/WNL.56.7.849","article-title":"Familial cerebellar ataxia with muscle coenzyme Q10 deficiency","volume":"56","author":"Musumeci","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.trsl.2020.08.009_bib0026","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/ph203134","article-title":"Coenzyme Q10 and neurological diseases","volume":"2","author":"Mancuso","year":"2009","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.trsl.2020.08.009_bib0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biof.5520320113","article-title":"Human CoQ10 deficiencies","volume":"32","author":"Quinzii","year":"2008","journal-title":"BioFactors"},{"key":"10.1016\/j.trsl.2020.08.009_bib0028","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.2174\/092986711796957257","article-title":"Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues","volume":"18","author":"Orsucci","year":"2011","journal-title":"Curr Med Chem"},{"issue":"Suppl","key":"10.1016\/j.trsl.2020.08.009_bib0029","article-title":"Friedreich's ataxia: coenzyme Q10 and vitamin E therapy","volume":"7","author":"Cooper","year":"2007","journal-title":"Mitochondrion"},{"key":"10.1016\/j.trsl.2020.08.009_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1179\/1351000213Y.0000000073","article-title":"Aconitase post-translational modification as a key in linkage between Krebs cycle, iron homeostasis, redox signaling, and metabolism of reactive oxygen species","volume":"19","author":"Lushchak O","year":"2014","journal-title":"Redox Rep"},{"key":"10.1016\/j.trsl.2020.08.009_bib0031","article-title":"Pharmacological treatments for Friedreich ataxia","volume":"2016","author":"Kearney","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trsl.2020.08.009_bib0032","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(99)01341-0","article-title":"Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study","volume":"354","author":"Rustin","year":"1999","journal-title":"Lancet"},{"issue":"Suppl1","key":"10.1016\/j.trsl.2020.08.009_bib0033","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jnc.12322","article-title":"Co-enzyme Q10 and idebenone use in Friedreich's ataxia","volume":"126","author":"Parkinson","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.trsl.2020.08.009_bib0034","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/mds.25058","article-title":"A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial","volume":"27","author":"Lynch","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.trsl.2020.08.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214250","article-title":"Targeting ferroptosis: a novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy","volume":"14","author":"Kahn-Kirby","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.08.009_bib0036","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/nmt-2018-0013","article-title":"Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia","volume":"8","author":"Zesiewicz","year":"2018","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.trsl.2020.08.009_bib0037","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ng1097-215","article-title":"Aconitase and mitochondrial iron\u2013sulphur protein deficiency in Friedreich ataxia","volume":"17","author":"R\u00f6tig","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2020.08.009_bib0038","first-page":"268","article-title":"Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management","volume":"10","author":"Kidd","year":"2005","journal-title":"Altern Med Rev"},{"key":"10.1016\/j.trsl.2020.08.009_bib0039","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.expneurol.2008.08.013","article-title":"Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy","volume":"214","author":"Melli","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-004-0216-x","article-title":"L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial","volume":"112","author":"Sch\u00f6ls","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.trsl.2020.08.009_bib0041","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-7091-0579-5_16","article-title":"Therapeutic strategies in Friedreich's ataxia","author":"Sch\u00f6ls","year":"2004","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.trsl.2020.08.009_bib0042","doi-asserted-by":"crossref","first-page":"e8872","DOI":"10.1371\/journal.pone.0008872","article-title":"Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency","volume":"5","author":"Gonzalez-Cabo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.08.009_bib0043","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12311-013-0482-y","article-title":"Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial","volume":"12","author":"Arpa","year":"2013","journal-title":"Cerebellum"},{"key":"10.1016\/j.trsl.2020.08.009_bib0044","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ane.12141","article-title":"Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia\u2014open-label trial","volume":"129","author":"Arpa","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.trsl.2020.08.009_bib0045","article-title":"Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2020.08.009_bib0046","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-019-1627-9","article-title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","volume":"16","author":"Zhao","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.trsl.2020.08.009_bib0047","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1093\/hmg\/11.24.3055","article-title":"A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy","volume":"11","author":"Jauslin","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.trsl.2020.08.009_bib0048","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0049","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0050","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","article-title":"An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels","volume":"262","author":"Yiu","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0051","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/mds.27353","article-title":"Randomized, clinical trial of RT001: early signals of efficacy in Friedreich's ataxia","volume":"33","author":"Zesiewicz","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.trsl.2020.08.009_bib0052","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40263-013-0124-4","article-title":"Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone","volume":"28","author":"Liu","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.trsl.2020.08.009_bib0053","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.expneurol.2009.04.001","article-title":"Alpha-lipoic acid and frataxin: a new indication for an old antioxidant?","volume":"218","author":"Russell","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0054","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.addr.2008.05.001","article-title":"The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies","volume":"60","author":"Tarnopolsky","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl 3","key":"10.1016\/j.trsl.2020.08.009_bib0055","article-title":"Bioenergetic approaches for neuroprotection in Parkinson's disease","volume":"53","author":"Beal","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.trsl.2020.08.009_bib0056","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mus.20688","article-title":"Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders","volume":"35","author":"Rodriguez","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.trsl.2020.08.009_bib0057","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/1567-1364.12134","article-title":"Mitochondria in ageing: there is metabolism beyond the ROS","volume":"14","author":"Breitenbach","year":"2014","journal-title":"FEMS Yeast Res"},{"key":"10.1016\/j.trsl.2020.08.009_bib0058","doi-asserted-by":"crossref","first-page":"20169","DOI":"10.3390\/ijms151120169","article-title":"Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials","volume":"15","author":"Pagano","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2020.08.009_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9010082","article-title":"Mitoprotective clinical strategies in type 2 diabetes and fanconi anemia patients: suggestions for clinical management of mitochondrial dysfunction","volume":"9","author":"Pagano","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.trsl.2020.08.009_bib0060","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1080\/14656566.2019.1639671","article-title":"New developments in pharmacotherapy for Friedreich ataxia","volume":"20","author":"Clay","year":"2019","journal-title":"Expert Opin Pharmacother"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524420302048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524420302048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:41:21Z","timestamp":1761828081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524420302048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":60,"alternative-id":["S1931524420302048"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2020.08.009","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}